CD63 and ovarian cancer: This platform was able to efficiently capture EVs by anti-CD81 antibody and discriminate plasma EVs derived from ovarian cancer patients (n = 7) from the healthy controls (n = 5) by the mixture containing three biomarkers (CD63, CD81, and EpCAM).